Introduction. An important problem in oncology is the creation of sets of markers for early differential diagnosis of tumors, determining cancer progress and response to therapy. Markers, which are already in use, are effective at the later stages of tumor development. Therefore, it is necessary to intensify the search for new markers, both, genetic and epigenetic, which reflect the changes at the early stages of carcinogenesis.
The present work is aimed at clarifying genetic and epigenetic alterations that occur during carcinogenesis and designing perspective sets of newly identified biomarkers.
Microarray analysis of large-scale searches for epigenetic changes in cancers (comparison of tumor versus normal tissues). NotI-microarray technology.
The search for tumor markers is a complicated, multistep process. The first step, usually, is the identification of large-scale genetic and/or epigenetic changes of the genome. The new type of microarrays that was recently developed in our group opens new possibilities for extensive studies of methylation patterns in normal and cancer tissues [1] . The main objective was to prepare NotI microarrays (NMA, i. e. glass microarrays with attached NotI DNA fragments) for comparing the normal and malignant cell genomes. Since the NotI enzyme cuts only unmethylated CpG pairs in the recognition site, (5'-GCGGCCGC-3'), only a small fraction of the NotI digested fragments (0.1-0.5 %) becomes labeled [2] . Thus, in contrast to all other methods, only digested DNA fragments were labeled. As a consequence, the probes contained 10-fold less repeats, were less sensitive to incomplete digestion, and gave less background. A simplified scheme of a NotI microarray analysis protocol is presented in Fig. 1 .
Results and confirmation of the NotI microarray analysis of epithelial tumors. It is known, that the short arm of human chromosome 3 is involved in the development of many epithelial cancers [3] [4] [5] [6] [7] . Epithelial tumors make up~90 % of all malignant tumors. The tumors of kidney, cervix, colon, ovary, and lung were analyzed in our work, using the chromosome 3 specific NotI microarrays (NMA), which contained 180 NotI linking clones, associated with 188 genes [8] . For all studied cancers we found genes, specifically methyla-ted in malignant cells. Many genes were methylated in a very high percentage of cancer samples. These genes can be divided into two classes: cancer specific and common for several types of cancer. The genes, MINT24, BHLB2, GATA-2, RARB1, RBSP3, VHL, LRRC3B [1] , were involved in several cancers.
Interestingly, many methylated genes were prevoiusly unknown to be involved in the development of epithelial cancers. To prove the methylation status of genes that were observed by NMA hybridization, the methyl specific PCR (MSP) and bisulfite sequencing were performed. Genes that changed methylation status have been further investigated by relative genes expression, using Q-PCR [9] .
Below we present some examples of changes in epigenetic profiles of certain genes in epithelial tumors. Primary tumors of different types of non-small cell lung carcinoma (NSCLC) were studied [10] , namely, squamous cell carcinoma (SCC), and adenocarcinoma (ADC) (Fig. 2 , A, Supplement) [11] .
Results of the NMA hybridization have shown that 44 loci/genes were methylated and/or deleted with a frequency from 15 to 58 % (Fig. 2 , B, Supplement) [11] .
Methylation was observed at stage I of SCC tumors. In ADC any of the genes showed methylation patterns, characteristic for tumor progression stage.
From the frequently methylated genes by NMA, two genes were chosen and their methylation was additionally tested, using bisulfite sequencing -VHL (in one SCC tumor sample and one ADC -tumor sample) and ITGA9 (in four SCC tumor samples). In all tested cases the methylation pattern was confirmed [11] .
Ten genes that showed high methylation and/or deletion frequencies in NSCLC were tested for expression; these genes were expressed at the decreased level in 30-90 % of ADC cases and 38-100 % of SCC cases (Fig. 3 ). In general, the mRNA level in SCC samples was more frequently down-regulated than in ADC (statistically valid for ITGA9 (P = 0.02) and FOXP1 (P = = 0.05) genes). In SCC, down-regulation was observed in 70 % of samples already at stage I, and in ADConly in 45 %. Seven genes (except LRRN1, FGD5 and ALDH1L1) showed increased frequencies and/or down regulated expression upon the metastasizing of ADC (P < 0.05 for RBSP3 (CTDSPL) and ITGA9 genes). The same tendencies were observed for other 5 genes in SCC (IQSEC1, FOXP1 (P < 0.05), LRRN1, FGD5 and BCL6 [11] ).
The NMA was used to analyze other types of cancers, namely, tumors of the cervix.
17 NotI-linking clones were detected that showed changes in more than 35 % of all of investigated tumor samples. The 7 of them were associated with other human cancers: MINT24, BHLHB2, ITGA9, RPL15, RARbeta1, RBSP3, and VHL. Some of them are accepted tumor suppressor genes, for example, LRRC3B and WNT7A [12, 13] .
The 27 genes/loci showed differential expression in colorectal cancers compared with normal tissues in more than 30% of the tumor samples. [14] . The 6 genes/ loci of the 27 were specific for colorectal cancer. The role of this six genes/loci (CKLFSF6, PLCL2, LMCD1, NUDT16P, LOC131961 and LOC650370) in the initiation and progression of tumors remains unknown and further study is required. Several genes/loci that were identified in our study as altered genes include previously described bona fide tumor suppressor genes: VHL, RBSP3, WNT7A, ITGA9, and FOXP1 [15] . GORDIYUK V. V., KONDRATOV A. G., GERASHCHENKO A. V., KASHUBA V. I. Fig. 1 . A simplified scheme of the NotI microarray analysis protocol: A -isolation of genomic DNA; B -digestion with the methylspecific rare-cutter enzyme NotI; C -ligation of fragments with the NotI-linker containing biotin; D -digestion with the 4-base pair recognizing restriction enzyme Sau3AI; E -conjugation to microbeads, containing streptavidin and washing; F -amplification of DNA sequences that have been attached to microbeads. The standard procedures were performed then: microarray hybridization, cloning, and sequencing analysis NMA of ovarian cancers has revealed that 35 genes showed the highest percentage of alterations (methylation and/or deletion). The 17 genes/loci showed changes in more than 30 % of ovarian tumor samples, regardless whether the tumors were malignant or benign [16] . The most essential changes in tumor samples were found for LRRC3B (80 %), RARB (73 %), GATA2, and NKIRAS1 (66 %) genes [17] . NMA results have shown that the majority of genes with high frequency of changes in epithelial cancers are located on 3p21 and 3p24 regions [18] [19] [20] [21] .
Several genes were selected and further analyzed. For example, methylation of the LRRC3B gene in colorectal cancer was investigated, and, based on the obtained results, this gene was proposed as a methylsensitive gene for diagnostics [22] . Also, the expression of LRRC3B gene in breast, cervical, lung, RCC, ovarian, and colon cancers was tested, using Q-PCR. LRRC3B gene expression was unchanged in ccRCC at stages I and II, however, it was 26-fold decreased in tumors at stage III. Noteworthy, this gene did not show difference in the expression pattern in ovarian cancers without metastases, while it was 46-fold decreased in a sample with lymph node metastases (T3N1M0) and 107-fold less in a sample with distant metastases (T4N1M1) [23] .
Using NMA technology the set of frequently affected genes/loci of chromosome 3 was revealed in renal cell carcinomas (RCC's) [20] . Briefly, we have identified 15 genes, which had genetic (deletion, amplification) and/or epigenetic (DNA methylation/demethylation) alterations in more than 30 % of RCC samples. Among frequently affected genes were NKIRAS1/ RPL15, MINT24, LRRC3B, VHL, RBSP3, GORASP1, RARB, NBEAL2, GNAI, PPM1M, FOXP1 and ZIC4. Additionally, using NMA we have detected the genetic/ epigenetic changes for some cancer associated genes like WNT7A, FOXP1 and ITGA9 in ccRCC's [20] .
We have performed the NMA data verification by routine methods for some of the identified genes. Thus, we showed hypermethylation of the LRRC3B promoter CpG-island in 43 % of clear cell RCC's [12] . Moreover, the restoration of LRRC3B expression led to a significant decrease of colony formation by KRC/Y cell line [23] .
It was identified that the NKIRAS1 expression was down-regulated in 75 % of ccRCC samples (9 of 12) compared to surrounding normal tissue. This was accompanied by copy number change of the NKIRAS1 gene, which was observed in 64 % (9 of 14) of ccRCC samples [17] . Hypermethylation and high deletion frequency of the WNT7A gene were detected in 66 % (29/ 44) and 85% (23/27) of analyzed ccRCC's. In addition, the re-expression of WNT7A led to inhibition of the proliferation rate in RCC cell lines [13] . Therefore, application of NMA technology contributed to identification of the frequently hypermethylated genes in ccRCC.
Subsequently we have used the newly detected LRRC3B gene in combination with well-known hypermethylated genes such as APC and FHIT to create a methylation-based biomarker panel for diagnostics of RCC [24] [25] [26] . We have detected hypermethylation of LRRC3B, FHIT and APC genes in 33.3 %, 27.8 % and 33.8 % of plasma samples of the RCC patients. These data emphasize the perspective application of NMA te- chnology for identification of new methylation-based biomarkers [27] .
NOVEL EPIGENETIC MARKERS OF EARLY EPITHELIAL TUMOR GROWTH AND PROGNOSIS

Lung squamous cell carcinoma
Selection of genes/biomarkers for detection and status of epithelial cancers. Thus, we have completed the first stage of the search for biomarkers. We found a number of epigenetic changes in certain genes in different tumor types. The next step was to select genes for biomarker panels. One of the examples of such panels to distinguish benign and malignant tumors was the NotIlinking clones forming DNA-microarray chips. These panels were used to investigate lung and ovary cancers [11, 16] .
If methylation and/or deletion were found in two or more genes of a biomarker panel, such sets would be then recognized as specific groups. In this way, the NMA results afforded an opportunity to select some of the genes with high levels of epigenetic changes for the next stage of marker detection. A cluster analysis permits the putative gene selection to discriminate different stages of cancerogenesis. Based on our results, we can propose a set of 8 genes for detection of NSCLC in lung biopsies of all stages, including stage I (Table 1, A) [11] . To select the genes that can help to discriminate ADC without metastases from the three other groups, i. e., ADC with metastases, SCC without and with metastases, was quite easy, using [the] data, obtained by NotI microarray analysis. To distinguish ADC from SCC, the most promising set should include NKIRAS1/ RPL15, CGGBP1, VHL, LOC285375, EPHB1, BHL HE40, and ANKRD28 biomarkers (Table 1, B) [11] .
For discrimination between ADC without and with metastases, it is possible to use LRRC3B, UBE2E2, WNT7A, and FGD5 set of biomarkers (Table 1, C) [11] .
Using the obtained NotI microarrays data with comparatively small number of samples, it was quite difficult to discriminate between SCC cases without and with metastases (Table 1, D) [11] . The most suitable set consists of only three genes (GORASP1/TTC21A, LRRN1, and VHL) that showed increased frequencies of methylation and/or deletion upon progression of SCC, and one gene -MITF showed an opposite trend, i. e. the decreased frequency of methylation and/or deletion. If deletions and/or methylation were not detected for any of the three down-regulated genes, one point was given for each gene in which methylation was not found (no point counts if changes were detected) in the sample [11] .
Concluding, a comprehensive statistical analysis suggested a set of 19 gene markers for the early detection, characteristics of tumor progression, prognosis of metastasizing, and for discrimination between SCC and ADC with sensitivity and specificity of 80-100 % (Table 1, A-D) [11] .
For detection of cancer cells in ovarian biopsies of all stages, including early one, the most perspective set from analyzed genes was the set of 8 biomarkers (Table  2 , A) [16] .
For discrimination between benign and malignant tumors it is possible to use the set of 8 biomarkers (Table 2, B) [16] .
To distinguish between stages I + II and stages III + + IV of ovarian cancer the most promising set should include 5 biomarkers (Table 2, C) [16] .
Summarizing the obtained data, the set of 10 gene markers was developed for early detection and discrimination of ovarian cancer groups with different histological characteristics [16] . N o t e. Sp* -specificity; Sn** -sensitivity of the set; P*** -parameter shows significance of compared groups distinction, calculated using Fisher exact test and c 2 criteria. N o t e. Sp* -specificity; Sn** -sensitivity of the set; P*** -parameter shows significance of compared groups distinction, calculated using Fisher exact test and c 2 criteria. Table 2 Early detection and discrimination of ovarian cancer groups with different histological characteristics, using the set of 11 selected gene
